Drug
Orteronel clinical trials
Also written TAK-700.
- studies test it
- 18
- open now
- 0
- in phase 3
- 6
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 4 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 11
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 12
Millennium Pharmaceuticals, Inc. (6) · University of Wisconsin, Madison (2) · Swiss Group for Clinical Cancer Research (2) · Radiation Therapy Oncology Group (1) · SWOG Cancer Research Network (1) · SCRI Development Innovations, LLC (1) · Grupo Español de Tumores Huérfanos e Infrecuentes (1) · University of Southern California (1)
Often tested with
Tested in the same studies.
Prednisone (2) · Docetaxel (1) · Gonadotropin-releasing Hormone Analog (1) · Itraconazole (1)
Studies
Open first, then newest update. How each study uses orteronel is read from its arms, and is right about nine times in ten.
Testing it · 18
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate CancerCompletedPhase 3Radiation Therapy Oncology GroupNCT01546987Written as TAK-700
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerCompletedPhase 3SWOG Cancer Research NetworkNCT01809691Written as TAK-700
- Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)CompletedPhase 2SCRI Development Innovations, LLCNCT01990209Written as Orteronel
- NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone MetastasisTerminatedPhase 2University of Wisconsin, MadisonNCT01816048Written as TAK-700
- A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast CancerCompletedPhase 1University of Wisconsin, MadisonNCT01808040Written as TAK700
- Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate CancerCompletedPhase 1/2Millennium Pharmaceuticals, Inc.NCT01084655Written as TAK-700
- Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel TherapyCompletedPhase 3Swiss Group for Clinical Cancer ResearchNCT01707966Written as Orteronel
- Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.CompletedPhase 3Millennium Pharmaceuticals, Inc.NCT01193257Written as Orteronel
- Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal AgentsWithdrawnPhase 3Swiss Group for Clinical Cancer ResearchNCT02053311Written as Orteronel
- Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.TerminatedPhase 2Grupo Español de Tumores Huérfanos e InfrecuentesNCT02101684Written as Orteronel 300mg BID
- Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedPhase 2University of Southern CaliforniaNCT01866423Written as orteronel
- A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery AloneTerminatedPhase 2Centre of Experimental MedicineNCT03211052Written as TAK-700 and LHRH agonist
- Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate CancerCompletedPhase 3Millennium Pharmaceuticals, Inc.NCT01193244Written as Orteronel
- TAK-700 in Castration Resistant Prostate CancerWithdrawnPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT01658527Written as Orteronel
- Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT01549951Written as Orteronel+Prednisone
- Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific AntigenCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT01046916Written as TAK-700
- Safety Study of TAK-700 in Subjects With Prostate Cancer.CompletedPhase 1/2Millennium Pharmaceuticals, Inc.NCT00569153Written as TAK-700
- Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)WithdrawnPhase 1/2Emmanuel Antonarakis, MDNCT02054793Written as Orteronel
Given in every arm · 1 — orteronel is usual care beside what is tested
Codes
What other systems call orteronel · ClinicalTrials.gg INT006046
- MeSH (NLM) C571806orteronelOne source NLM
- UNII (FDA) UE5K2FNS92ORTERONELConfirmed FDA, NLM, Wikidata
- Wikidata Q6581305OrteronelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90582OrteronelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571806 | orteronel | One source NLM |
| UNII (FDA) | UE5K2FNS92 | ORTERONEL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6581305 | Orteronel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90582 | Orteronel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.